Legal Representation
Attorney
Mark Lerner
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 1, 2007 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 1, 2007 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Sep 26, 2006 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 26, 2006 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 26, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 10, 2006 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 27, 2006 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 28, 2006 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Mar 28, 2006 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Mar 28, 2006 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Sep 27, 2005 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 17, 2005 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Jul 22, 2005 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED | Loading... |
| Jul 15, 2005 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 15, 2005 | FAXX | I | FAX RECEIVED | Loading... |
| Jul 15, 2005 | FAXX | I | FAX RECEIVED | Loading... |
| Feb 2, 2005 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Jan 18, 2005 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 29, 2004 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Nov 18, 2004 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Nov 18, 2004 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 15, 2004 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 29, 2004 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 29, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 15, 2004 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
use as a housemark for Vaccines, therapeutic vaccines and therapeutic pharmaceuticals derived from monoclonal antibodies for use in the treatment of cancer, autoimmune disorders, infectious diseases and graft-verus-host disease
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005